Browsing by Author "Stoop, Thomas F."

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Global Survey on Pancreatic Surgery During the COVID-19 Pandemic
    (Lippincott Williams & Wilkins, 2020-06-24) Oba, Atsushi; Stoop, Thomas F.; Löhr, Matthias; Hackert, Thilo; Zyromski, Nicholas; Nealon, William H.; Unno, Michiaki; Schulick, Richard D.; Al-Musawi, Mohammed H.; Wu, Wenming; Zhao, Yupei; Satoi, Sohei; Wolfgang, Christopher L.; Hilal, Mohammad Abu; Besselink, Marc G.; Del Chiaro, Marco; Surgery, School of Medicine
    This global survey among members of seven international pancreatic associations and study groups elucidates the role of pancreatic surgery during the COVID-19 pandemic, regarding patient selection for the surgical and oncological treatment of pancreatic diseases to support clinical decision-making and creating a starting point for further discussion.
  • Thumbnail Image
    Item
    Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy
    (American Medical Association, 2024-06-03) Stoop, Thomas F.; Oba, Atsushi; Wu, Y. H. Andrew; Beaty, Laurel E.; Colborn, Kathryn L.; Janssen, Boris V.; Al-Musawi, Mohammed H.; Rodriguez Franco, Salvador; Sugawara, Toshitaka; Franklin, Oskar; Jain, Ajay; Saiura, Akio; Sauvanet, Alain; Coppola, Alessandro; Javed, Ammar A.; Groot Koerkamp, Bas; Miller, Braden N.; Mack, Claudia E.; Hashimoto, Daisuke; Caputo, Damiano; Kleive, Dyre; Sereni, Elisabetta; Belfiori, Giulio; Ichida, Hirofumi; van Dam, Jacob L.; Dembinski, Jeanne; Akahoshi, Keiichi; Roberts, Keith J.; Tanaka, Kimitaka; Labori, Knut J.; Falconi, Massimo; House, Michael G.; Sugimoto, Motokazu; Tanabe, Minoru; Gotohda, Naoto; Krohn, Paul S.; Burkhart, Richard A.; Thakkar, Rohan G.; Pande, Rupaly; Dokmak, Safi; Hirano, Satoshi; Burgdorf, Stefan K.; Crippa, Stefano; van Roessel, Stijn; Satoi, Sohei; White, Steven A.; Hackert, Thilo; Nguyen, Trang K.; Yamamoto, Tomohisa; Nakamura, Toru; Bachu, Vismaya; Burns, William R.; Inoue, Yosuke; Takahashi, Yu; Ushida, Yuta; Aslami, Zohra V.; Verbeke, Caroline S.; Fariña, Arantza; He, Jin; Wilmink, Johanna W.; Messersmith, Wells; Verheij, Joanne; Kaplan, Jeffrey; Schulick, Richard D.; Besselink, Marc G.; Del Chiaro, Marco; Surgery, School of Medicine
    Importance: Preoperative chemo(radio)therapy is increasingly used in patients with localized pancreatic adenocarcinoma, leading to pathological complete response (pCR) in a small subset of patients. However, multicenter studies with in-depth data about pCR are lacking. Objective: To investigate the incidence, outcome, and risk factors of pCR after preoperative chemo(radio)therapy. Design, setting, and participants: This observational, international, multicenter cohort study assessed all consecutive patients with pathology-proven localized pancreatic adenocarcinoma who underwent resection after 2 or more cycles of chemotherapy (with or without radiotherapy) in 19 centers from 8 countries (January 1, 2010, to December 31, 2018). Data collection was performed from February 1, 2020, to April 30, 2022, and analyses from January 1, 2022, to December 31, 2023. Median follow-up was 19 months. Exposures: Preoperative chemotherapy (with or without radiotherapy) followed by resection. Main outcomes and measures: The incidence of pCR (defined as absence of vital tumor cells in the sampled pancreas specimen after resection), its association with OS from surgery, and factors associated with pCR. Factors associated with overall survival (OS) and pCR were investigated with Cox proportional hazards and logistic regression models, respectively. Results: Overall, 1758 patients (mean [SD] age, 64 [9] years; 879 [50.0%] male) were studied. The rate of pCR was 4.8% (n = 85), and pCR was associated with OS (hazard ratio, 0.46; 95% CI, 0.26-0.83). The 1-, 3-, and 5-year OS rates were 95%, 82%, and 63% in patients with pCR vs 80%, 46%, and 30% in patients without pCR, respectively (P < .001). Factors associated with pCR included preoperative multiagent chemotherapy other than (m)FOLFIRINOX ([modified] leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) (odds ratio [OR], 0.48; 95% CI, 0.26-0.87), preoperative conventional radiotherapy (OR, 2.03; 95% CI, 1.00-4.10), preoperative stereotactic body radiotherapy (OR, 8.91; 95% CI, 4.17-19.05), radiologic response (OR, 13.00; 95% CI, 7.02-24.08), and normal(ized) serum carbohydrate antigen 19-9 after preoperative therapy (OR, 3.76; 95% CI, 1.79-7.89). Conclusions and relevance: This international, retrospective cohort study found that pCR occurred in 4.8% of patients with resected localized pancreatic adenocarcinoma after preoperative chemo(radio)therapy. Although pCR does not reflect cure, it is associated with improved OS, with a doubled 5-year OS of 63% compared with 30% in patients without pCR. Factors associated with pCR related to preoperative chemo(radio)therapy regimens and anatomical and biological disease response features may have implications for treatment strategies that require validation in prospective studies because they may not universally apply to all patients with pancreatic adenocarcinoma.
  • Thumbnail Image
    Item
    Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Patients in North America, Germany, Sweden, and The Netherlands (GAPASURG)
    (Springer, 2024) Stoop, Thomas F.; Augustinus, Simone; Björnsson, Bergthor; Tingstedt, Bobby; Andersson, Bodil; Wolfgang, Christopher L.; Werner, Jens; Johansen, Karin; Stommel, Martijn W. J.; Katz, Matthew H. G.; Ghadimi, Michael; House, Michael G.; Ghorbani, Poya; Molenaar, I. Quintus; de Wilde, Roeland F.; Mieog, J. Sven D.; Keck, Tobias; Wellner, Ulrich F.; Uhl, Waldemar; Besselink, Marc G.; Pitt, Henry A.; Del Chiaro, Marco; Global Audits on Pancreatic Surgery Group (GAPASURG); Surgery, School of Medicine
    Background: Pancreatic adenocarcinoma located in the pancreatic body might require a portomesenteric venous resection (PVR), but data regarding surgical risks after distal pancreatectomy (DP) with PVR are sparse. Insight into additional surgical risks of DP-PVR could support preoperative counseling and intraoperative decision making. This study aimed to provide insight into the surgical outcome of DP-PVR, including its potential risk elevation over standard DP. Methods: We conducted a retrospective, multicenter study including all patients with pancreatic adenocarcinoma who underwent DP ± PVR (2018-2020), registered in four audits for pancreatic surgery from North America, Germany, Sweden, and The Netherlands. Patients who underwent concomitant arterial and/or multivisceral resection(s) were excluded. Predictors for in-hospital/30-day major morbidity and mortality were investigated by logistic regression, correcting for each audit. Results: Overall, 2924 patients after DP were included, of whom 241 patients (8.2%) underwent DP-PVR. Rates of major morbidity (24% vs. 18%; p = 0.024) and post-pancreatectomy hemorrhage grade B/C (10% vs. 3%; p = 0.041) were higher after DP-PVR compared with standard DP. Mortality after DP-PVR and standard DP did not differ significantly (2% vs. 1%; p = 0.542). Predictors for major morbidity were PVR (odds ratio [OR] 1.500, 95% confidence interval [CI] 1.086-2.071) and conversion from minimally invasive to open surgery (OR 1.420, 95% CI 1.032-1.970). Predictors for mortality were higher age (OR 1.087, 95% CI 1.045-1.132), chronic obstructive pulmonary disease (OR 4.167, 95% CI 1.852-9.374), and conversion from minimally invasive to open surgery (OR 2.919, 95% CI 1.197-7.118), whereas concomitant PVR was not associated with mortality. Conclusions: PVR during DP for pancreatic adenocarcinoma in the pancreatic body is associated with increased morbidity, but can be performed safely in terms of mortality.